• Vaccine Name: Bovine herpesvirus 1 DNA vaccine AdCMVgC
• Target Pathogen: Bovine herpesvirus 1
• Target Disease: Infectious bovine rhinotracheitis
• Vaccine Ontology ID: VO_0011382
• Type: DNA vaccine
• Status: Research
• Antigen: Bovine herpesvirus 1 glycoprotein C
• UL44 gene engineering:
  • Type: DNA vaccine construction
  • Description: For the gC gene, a SpeI–NotI fragment (containing the gC gene) was extracted from pSKgC and cloned into pCi to yield plasmid pCigC. The expression cassettes containing the CMV promoter, splicing signals, glycoprotein gene, and SV40 polyadenylation signal, were extracted as BamHI–BglII fragments that were cloned into the BamHI site of plasmid pAd-link, resulting in plasmid pAdCMVgC (Gogev et al., 2002).
  • Detailed Gene Information: Click Here.
• DNA vaccine plasmid:
  • DNA vaccine plasmid name:
  • DNA vaccine plasmid VO ID: VO_0000212
• Immunization Route: Intranasal

Cattle Response

• Vaccination Protocol: Twenty-eight calves, 6–8 months old, were randomly allocated into five groups of five calves and one group of three calves. Three groups were inoculated twice 3 weeks apart by the intranasal route with 2 ml per nostril with a semi-purified preparation at a dose of 1010 CCID50 (Cell Culture Infectious Dose) of either AdCMVgC, or AdCMVgD or a combination of these two recombinants (5×10^9 CCID50 of AdCMVgC+5×10^9 CCID50 of AdCMVgD). At days 0 and 21, one group was inoculated twice by the intranasal route with a commercially available live vaccine whereas the group of three animals was inoculated intranasally twice 3 weeks apart with inactivated AdCMVgD, inactivated AdCMVgC, and a combination of them. One group was not inoculated and served as control (Gogev et al., 2002).
• Challenge Protocol: On day 42, calves were challenged by the intranasal route with 5×10^6 plaque forming units (PFU) of BHV-1 IOWA strain. Calves were clinically examined and rectal temperatures were measured for 2 weeks after each immunization and for 3 weeks following the challenge performed on day 42 (Gogev et al., 2002).
• Efficacy: The administration of either Ad5CMVgD or Ad5CMVgC, or a combination of them in calves by intranasal route 3 weeks apart, induced BHV-1 neutralizing antibody responses and conferred protection against challenge with BHV-1 Iowa strain (Gogev et al., 2002).